ES2190784T3 - Supresion de enfermedades autoinmunes por antigenos espectadores. - Google Patents

Supresion de enfermedades autoinmunes por antigenos espectadores.

Info

Publication number
ES2190784T3
ES2190784T3 ES93907044T ES93907044T ES2190784T3 ES 2190784 T3 ES2190784 T3 ES 2190784T3 ES 93907044 T ES93907044 T ES 93907044T ES 93907044 T ES93907044 T ES 93907044T ES 2190784 T3 ES2190784 T3 ES 2190784T3
Authority
ES
Spain
Prior art keywords
specting
antigens
suppression
autoimmune diseases
autoantigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93907044T
Other languages
English (en)
Inventor
Howard L Weiner
Ariel Miller
Zhengri Zhang
Ahmad Al-Sabbagh
David A Hafler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autoimmune Inc
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Application granted granted Critical
Publication of ES2190784T3 publication Critical patent/ES2190784T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Abstract

LA INVENCION SE REFIERE A UN METODO PAR EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES DE MAMIFEROS, EL CUAL CONSISTE EN ADMINISTRAR A LOS MAMIFEROS UNA CANTIDAD EFECTIVA PARA EL TRATAMIENTO DE LAS ENFERMEDADES DE UN ANTIGENO INOFENSIVO QUE PROVOCA LA LIBERACION DE LA HORMONA DE CRECIMIENTO DE TRANSFORMACION BETA (TGF(BETA)) EN UN LUGAR DENTRO DEL CUERPO DE LOS MAMIFEROS EN DONDE SE HA DESCUBIERTO QUE LAS CELULAS T CONTRIBUYEN A UNA RESPUESTA AUTOINMUNE ELIMINAN LAS CELULAS T QUE CONTRIBUYEN A LA ENFERMEDAD. LA INVENCION SE REFIERE TAMBIEN A COMPOSICIONES QUE CONTIENEN ANTIGENOS INOFENSIVOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES DE MAMIFEROS Y A FORMULACIONES FARMACEUTICAS DE LAS MISMAS.
ES93907044T 1992-02-28 1993-02-25 Supresion de enfermedades autoinmunes por antigenos espectadores. Expired - Lifetime ES2190784T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84375292A 1992-02-28 1992-02-28

Publications (1)

Publication Number Publication Date
ES2190784T3 true ES2190784T3 (es) 2003-08-16

Family

ID=25290916

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93907044T Expired - Lifetime ES2190784T3 (es) 1992-02-28 1993-02-25 Supresion de enfermedades autoinmunes por antigenos espectadores.

Country Status (16)

Country Link
US (1) US20050208061A1 (es)
EP (1) EP0627933B1 (es)
JP (1) JP3712260B2 (es)
KR (1) KR950700082A (es)
AT (1) ATE228373T1 (es)
AU (2) AU3778593A (es)
BR (1) BR9306042A (es)
CA (1) CA2117492C (es)
DE (1) DE69332518T2 (es)
DK (1) DK0627933T3 (es)
ES (1) ES2190784T3 (es)
HU (1) HU220357B (es)
IL (1) IL104880A (es)
NO (1) NO319062B1 (es)
PT (1) PT627933E (es)
WO (1) WO1993016724A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869054A (en) * 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5645820A (en) * 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5641474A (en) * 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
AU674584B2 (en) * 1993-06-02 1997-01-02 Tvw Telethon Institute For Child Health Research Cryptic peptides for use in inducing immunologic tolerance
CA2185353A1 (en) * 1994-04-08 1995-10-19 David A. Hafler Treatment of autoimmune disease using oral tolerization and/or type i interferon
HUT76101A (en) * 1994-04-08 1997-06-30 Brigham & Womens Hospital Treatment of autoimmune disease using oral tolerization and/or th2-enhancing cytokines
CA2203629A1 (en) * 1994-10-25 1996-05-02 Dawn Smilek Compositions and treatment for multiple sclerosis
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
WO1997046253A2 (en) * 1996-06-03 1997-12-11 Powderject Vaccines, Inc. Immunotherapy for autoimmune disease
KR20000070460A (ko) * 1997-01-24 2000-11-25 왈리스 조 앤 메토트렉세이트와 공동으로 내성화를 사용한 자기면역질병의 치료
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
WO1999056763A1 (en) * 1998-05-07 1999-11-11 The Regents Of The University Of California Use of neglected target tissue antigens in modulation of immune responses
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
ATE367823T1 (de) * 2000-05-24 2007-08-15 Us Health E-selectin zur behandlung oder vorbeugung von schlaganfall
EP1842551A1 (en) * 2000-05-24 2007-10-10 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services E-selectin for treating or preventing stroke
US7897575B2 (en) 2000-05-24 2011-03-01 The United States Of America As Represented By The Department Of Health And Human Services Treatment and prevention of vascular dementia
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP2006517533A (ja) * 2003-01-23 2006-07-27 ロランティス リミテッド Ｎｏｔｃｈシグナル伝達経路のアクチベーターを用いる自己免疫疾患の治療
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2113560A1 (en) * 2008-04-28 2009-11-04 TXCell Compositions for treating an arthritic condition
PL219335B1 (pl) 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EA201390559A1 (ru) * 2010-10-15 2013-08-30 Альк-Абелло А/С Подавление иммунного ответа по типу гиперчувствительности неродственным антигеном, получаемым из материала-источника аллергенов
EP2627354B1 (en) * 2010-10-15 2015-07-15 ALK-Abelló A/S Suppression of a type 1 hypersensitivity immune response with an unrelated antigen
CA3211102A1 (en) 2012-06-21 2013-12-27 Northwestern University Peptide conjugated particles
CA2932532C (en) 2012-12-04 2021-06-22 Phosphorex, Inc. Microparticles and nanoparticles having negative surface charges
JP6725413B2 (ja) 2013-03-13 2020-07-15 クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド 炎症の治療のための免疫修飾粒子
EP3033102B2 (en) 2013-08-13 2023-12-20 Northwestern University Peptide conjugated particles
WO2017112899A1 (en) 2015-12-23 2017-06-29 Cour Pharmaceuticals Development Company Inc. Covalent polymer-antigen conjugated particles
WO2019217780A1 (en) 2018-05-11 2019-11-14 Phosphorex, Inc. Microparticles and nanoparticles having negative surface charges

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4985436A (en) * 1984-02-17 1991-01-15 Arizona Board Of Regents Composition of matter for inhibiting leukemias and sarcomas
CA1302880C (en) * 1986-07-25 1992-06-09 Peter Koepff Agents for the treatment of arthroses
US5645820A (en) * 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5399347A (en) * 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5843445A (en) * 1987-06-24 1998-12-01 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5869054A (en) * 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US5641474A (en) * 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
HUT61487A (en) * 1989-12-20 1993-01-28 Brigham & Womens Hospital Process for producing aerosol pharmaceutical composition comprising autoantigens
US5075112A (en) * 1990-02-12 1991-12-24 Cartilage Technologies Inc. Method of and dosage unit for inhibiting angiogenesis or vascularization in an animal using shark cartilage
HUT61896A (en) * 1990-03-02 1993-03-29 Autoimmune Inc Process for producing orally administrable pharmaceutical compositions comprising autoantigenes, suitable for improving down-control of autoimmune diseases
EP0553291B1 (en) * 1990-10-15 2006-03-08 Autoimmune, Inc. Treatment of autoimmune diseases by oral administration of autoantigens

Also Published As

Publication number Publication date
AU3754297A (en) 1997-11-20
HU220357B (hu) 2001-12-28
NO943151L (no) 1994-10-26
DK0627933T3 (da) 2003-03-24
EP0627933A1 (en) 1994-12-14
JP3712260B2 (ja) 2005-11-02
HUT74832A (en) 1997-02-28
US20050208061A1 (en) 2005-09-22
DE69332518D1 (de) 2003-01-09
JPH08504745A (ja) 1996-05-21
IL104880A (en) 1997-07-13
DE69332518T2 (de) 2003-09-04
AU3778593A (en) 1993-09-13
EP0627933B1 (en) 2002-11-27
PT627933E (pt) 2003-04-30
HU9402468D0 (en) 1994-10-28
CA2117492A1 (en) 1993-09-02
BR9306042A (pt) 1997-11-18
WO1993016724A1 (en) 1993-09-02
NO319062B1 (no) 2005-06-13
NO943151D0 (no) 1994-08-25
ATE228373T1 (de) 2002-12-15
KR950700082A (ko) 1995-01-16
AU720695B2 (en) 2000-06-08
IL104880A0 (en) 1993-06-10
EP0627933A4 (en) 1997-01-15
CA2117492C (en) 2009-04-07

Similar Documents

Publication Publication Date Title
ES2190784T3 (es) Supresion de enfermedades autoinmunes por antigenos espectadores.
KR930702026A (ko) 자기항원의 경구 투여에 의한 자기면역 질병의 치료
DE3854741T2 (de) Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen.
ES2107459T3 (es) Mejora de la regulacion represora de enfermedades autoinmunes por administracion oral o enteral de autoantigenos.
ES2144398T3 (es) Tratamiento mejorado de enfermedades autoinmunes mediante la administracion en aerosol de autoantigenos.
EA200401473A1 (ru) Предотвращение и лечение амилоидогенного заболевания